NAD+ is not a novel research peptide — it's a coenzyme present in every living cell, required for energy metabolism and DNA repair. What's actually being studied and debated is the delivery question: whether administering NAD+ itself, rather than the precursor molecules it's normally built from, is the better way to raise it.
What Is NAD+?
Nicotinamide adenine dinucleotide (NAD+) is a coenzyme central to mitochondrial energy production and cellular signaling. Levels decline systemically with age across multiple tissues, a pattern linked in the literature to age-associated metabolic and neurodegenerative conditions.
Mechanism of Action
NAD+ is a required substrate for two major classes of enzymes: PARPs (poly-ADP-ribose polymerases), which use it to repair DNA damage, and sirtuins, which use it to remove regulatory chemical tags from histones and other proteins — controlling gene expression, DNA repair, mitochondrial function, and inflammatory signaling. Both pathways consume NAD+ directly, which is part of why levels fall under sustained cellular stress.
The Delivery Question — Does Direct NAD+ Even Work That Way?
This is the least-marketed and most important part of the mechanism. At the concentrations used in IV/subcutaneous administration, NAD+ itself is largely hydrolyzed into nicotinamide mononucleotide (NMN) and converted to nicotinamide riboside (NR) before cells actually take it up — meaning the precursor pathway does the intracellular work regardless of which molecule you start with. NAD+'s poor ability to cross cell membranes directly is exactly why NMN and NR are argued by some researchers to be more efficient at raising intracellular NAD+ than administering NAD+ itself.
A 2026 retrospective real-world tolerability study directly compared four consecutive days of IV NAD+ against IV NR with 30-day follow-up — a rare head-to-head data point in a space that mostly relies on precursor-only research. Oral NMN and NR separately have been shown to roughly double circulating NAD+ after two weeks of supplementation, peaking 3–8 hours after intake.
As of this writing, there is no trial directly comparing clinical outcomes — not just NAD+ blood levels — between injectable NAD+ and its precursors. The tolerability comparison exists; the outcome comparison doesn't yet.
Where to Source NAD+ for Research
For legitimate research applications, purity and accurate dosing are critical. We only list vendors who provide third-party HPLC testing and batch-specific Certificates of Analysis.
View the NAD+ product page →Frequently Asked Questions
Is injectable NAD+ actually better than NMN or NR supplements?
Not established. At the doses typically used, injected NAD+ is largely broken down into NMN and converted to NR before cells absorb it — meaning the precursor pathway is doing the work either way. A 2026 study compared tolerability between IV NAD+ and IV NR directly, but no trial has yet compared their actual physiological outcomes.
Why does NAD+ decline with age?
NAD+ is consumed as a substrate by PARPs (DNA repair) and sirtuins (gene regulation) — both pathways draw it down under sustained cellular stress, which compounds with age-related increases in DNA damage and metabolic strain.
References
1. "NAD+ biosynthesis, aging, and disease." PMC. ncbi.nlm.nih.gov
2. "It takes two to tango: NAD+ and sirtuins in aging/longevity control." PMC. ncbi.nlm.nih.gov
3. "Intravenous infusion of nicotinamide adenine dinucleotide (NAD+) versus nicotinamide riboside (NR): a retrospective tolerability pilot study in a real-world setting." Frontiers in Aging, 2026. PMC. pmc.ncbi.nlm.nih.gov
This article contains affiliate links. Aura Protocols may earn a commission if you purchase through these links at no additional cost to you. All compounds are for research use only.